HbA1c in patients with intracranial meningiomas WHO grades I and II: A preliminary study.
HbA1c
meningiomas
metabolism
Journal
IUBMB life
ISSN: 1521-6551
Titre abrégé: IUBMB Life
Pays: England
ID NLM: 100888706
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
09
01
2020
revised:
16
02
2020
accepted:
21
02
2020
pubmed:
7
3
2020
medline:
16
11
2021
entrez:
6
3
2020
Statut:
ppublish
Résumé
Meningiomas are among the most common primary brain tumors. There is a growing need for novel ways of differentiating between benign (World Health Organization [WHO] grade I) and atypical (WHO grade II) meningiomas as well as for novel markers of the tumor's future behavior. A difference between glucose metabolism in atypical and benign meningiomas is well known. However, a significant correlation between the systemic metabolic status of the patient and the meningioma WHO grade has not yet been established. Our aim was to compare the WHO grades of intracranial meningiomas with the patient's HbA1c levels as a more reliable marker of the chronic systemic metabolic status than the fasting blood glucose value, which is usually looked at. We retrospectively analyzed 15 patients and compared their meningioma WHO grade with their preoperative HbA1c values. Our results show that patients with benign intracranial meningiomas have significantly lower HbA1c value. Conversely, patients with atypical intracranial meningiomas have higher HbA1c values. Furthermore, we showed that the proliferation factor Ki67 was statistically strongly correlated with the HbA1c value (p < .001. These results imply a possible positive correlation between meningioma cell proliferation and the chronic systemic glycemia. Further research in this area could not only lead to better understanding of meningiomas but could have significant clinical application.
Substances chimiques
Glycated Hemoglobin A
0
hemoglobin A1c protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1426-1432Informations de copyright
© 2020 International Union of Biochemistry and Molecular Biology.
Références
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016;131:803-820.
Shakir SI, Souhami L, Petrecca K, et al. Prognostic factors for progression in atypical meningioma. J Neurosurg. 2018;129(5):1240-1248.
Hanft S, Canoll P, Bruce JN. A review of malignant meningiomas: Diagnosis, characteristics, and treatment. J Neurooncol. 2010;99(3):433-443.
Rogers L, Barani I, Chamberlain M, et al. Meningiomas: Knowledge base, treatment outcomes, and uncertainties. A RANO review J Neurosurg. 2015;122(1):4-23.
Buttrick S, Shah AH, Komotar RJ, Ivan ME. Management of atypical and anaplastic meningiomas. Neurosurg Clin N Am. 2016;27(2):239-247.
Jenskinson MD, Weber DC, Haylock BJ, Mallucci CL, Zakaria R, Javadpour M. Atypical meningoma: Current management dilemmas and prospective clinical trials. J Neurooncol. 2015;121(1):1-7.
Apra C, Peyre M, Kalamarides M. Current treatment options for meningioma. Expert Rev Neurother. 2018;18(3):241-249.
Vasudevan HN, Braunstein SE, Philips JJ, et al. Comprehensive molecular profiling identifies FOXM1 as a key transcription factor for meningioma proliferation. Cell Rep. 2018;22(13):3672-3683.
Van de Nes JA, Griewank KG, Schmid KW, Grabellus F. Immunocytochemical analysis of glucose transporter protein-1 (GLUT-1) in typical, brain invasive, atypical and anaplastic meningioma. Neuropathology. 2015;35(1):24-36.
Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, De Michele DJ. Glucose utilization by intracranial meningiomas as an index of tumora aggressivity and probability of recurrence: A PET study. Radiology. 1987;164(2):521-526.
Cremerius U, Bares R, Weis J, et al. Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET. J Nucl Med. 1997;38(1):26-30.
Bharadwaj S, Venkatraghavan L, Mariappan R, et al. Serum lactate as a potential biomarker of non-glial brain tumors. J Clin Neurosci. 2015;22(10):1625-1627.
Stover JF, Hopf NJ, Perneczky A, Kempski OS. Unspecific metabolic blood parameters as used in clinical routine may differentiate malignant from benign cerebral tumors. Cancer Lett. 1995;95(1-2):147-152.
Bernardo BM, Orellana RC, Weisband YL, et al. Association between prediagnostic glucose, triglycerides, cholesterol and meningioma, and reverse causality. Br J Cancer. 2016;115(1):108-114.
Baranovicova E, Galanda T, Galanda M, et al. Metabolic profiling of blood plasma in patients with primary brain tumours: Basal plasma metabolites correlated with tumour grade and plasma biomarker analysis predicts feasibility of the successful statistical discrimination from healthy subjects-A preliminary study. IUBMB Life. 2019;71(12):1994-2002.
Seliger C, Meier CR, Becker C, et al. Metabolic syndrome in relation to risk of meningioma. Oncotarget. 2017;8(2):2284-2292.
Alexandru O, Ene L, Purcaru OS, et al. Plasma levels of glucose and insulin in patients with brain tumors. Curr Health Sci J. 2014;40(1):27-36.
Weykamp C. HbA1c: A review of analytical and clinical aspects. Ann Lab Med. 2013;33(6):393-400.
Motoishi M, Sawai S, Hori T, Yamashita N. The preoperative HbA1c level is an independent prognostic factor for the postoperative survival after resecton of non-small cell lung cancer in elderly patients. Surg Today. 2018;48(5):517-524.
Roser F, Nakamura M, Bellizona M, Ritz R, Ostertag H, Tatagiba MS. Proliferation potential of spinal meningiomas. Eur Spine J. 2006;15(2):211-215.
Wiemels WM, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010;99(3):307-314.
Edlinger M, Strohmaier S, Jonsson H, et al. Blood pressure and other metabolic syndrome factors and risk of brain tumour in the large population-based me-can cohort study. J Hypertens. 2012;30(2):290-296.
Benson VS, Kirichek O, Beral V, Green J. Menopausal hormone therapy and central nervous system tumor risk: Large UK prospective study and meta-analysis. Int J Cancer. 2015;136(10):2369-2377.
Pećina-Šlaus N, Kafka A, Lechpammer M. Molecular genetics of intracranial meningiomas with emphasis on canonical WNT signalling. Cancers (Basel). 2016;8(7):67.
Shao C, Bai LP, QI ZY, Hui GZ, Wang Z. Overweight, obesity and meningioma risk: A meta-analysis. PLoS One. 2014;9(2):e90167.
Neidermaier T, Behrens G, Schmid D, Schlecht I, Fischer B, Leitzmann MF. Body mass index, physical activity, and risk of adult meningioma and glioma: A meta-analysis. Neurology. 2015;85(15):1342-1350.
Seliger C, Meier CR, Becker C, et al. Diabetes, use of metformin, and the risk of meningioma. PLoS One. 2017;12(7):e0181089.
Schneider B, Pulhorn H, Rohrig B, Rainov NG. Predisposing conditions and risk factors for development of symptomatic meningioma in adults. Cancer Detect Prev. 2005;29(5):440-447.
Schlehofer B, Blettner M, Preston-Martin S, et al. Role of medical history in brain tumour development. Results from the international adult brain tumour study. Int J Cancer. 1999;82(2):155-160.
Lee JW, Kang KW, Park SH, et al. 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging. 2009;36(10):1574-1582.
Cornelius JF, Langen KL, Stoffels G, Hanggj D, Sabel M, Jakob Steiger H. Positron emission tomography imaging of meningioma in clinical practice: Review of literature and future directions. 2012;70(4):1033-1041.
Galldiks N, Albert NL, Sommerauer M, et al. PET imaging in patients with meningioma-report of the RANO/PET group. Neuro Oncol. 2017;19(12):1576-1587.
Shepard JG, Airee A, Dake AW, McFarland MS, Vora A. Limitations of A1c interpretation. South Med J. 2015;108(12):724-729.
Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV. An overview of meningiomas. Future Oncol. 2018;14(21):2161-2177.
Sahm F, Schwimpf D, Stichel D, et al. DNA methylation-based classification and grading system for meningioma: A multicentre, retrospective analysis. Lancet Oncol. 2017;18(5):682-694.
Coroller TP, Bi WL, Huynh E, et al. Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS One. 2017;12(11):e0187908.
Goldbrunner R, Minniti G, Preusser M, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17(9):e383-e391.
Wang Q, Tang SB, Song XB, et al. High-glucose concentrations change DNA methylation levels in human IVM oocytes. Hum Reprod. 2018;33(3):474-481.
Hall E, Dekker Nitert M, Volkov P, et al. The effects of high glucose exposure on global gene expression and DNA methylation in human pancreatic islets. Mol Cell Endocrinol. 2018;472:57-67.